Controlled Release of Hydrogen‐Carrying Perfluorocarbons for Ischemia Myocardium‐Targeting 19F MRI‐Guided Reperfusion Injury Therapy

AbstractHydrogen gas is recently proven to have anti‐oxidative and anti‐inflammation effects on ischemia‐reperfusion injury. However, the efficacy of hydrogen therapy is limited by the efficiency of hydrogen storage, targeted delivery, and controlled release. In this study, H2‐PFOB nanoemulsions (NEs) is developed with high hydrogen loading capacity for targeted ischemic myocardium precision therapy. The hydrogen‐carrying capacity of H2‐PFOB NEs is determined by gas chromatography and microelectrode methods. Positive uptake of H2‐PFOB NEs in ischemia‐reperfusion myocardium and the influence of hydrogen on 19F‐MR signal are quantitatively visualized using a 9.4T MR imaging system. The biological therapeutic effects of H2‐PFOB NEs are examined on a myocardial ischemia‐reperfusion injury mouse model. The results illustrated that the developed H2‐PFOB NEs can efficaciously achieve specific infiltration into ischemic myocardium and exhibit excellent antioxidant and anti‐inflammatory properties on myocardial ischemia‐reperfusion injury, which can be dynamically visualized by 19F‐MR imaging system. Moreover, hydrogen burst release induced by low‐intensity focused ultrasound (LIFU) irradiation further promotes the therapeutic effect of H2‐PFOB NEs with a favorable biosafety profile. In this study, the potential therapeutic effects of H2‐PFOB NEs is fully unfolded, which may hold great potential for future hydrogen‐based precision therapeutic applications tailored to ischemia‐reperfusion injury.

Topics

No keywords indexed for this article. Browse by subject →

References

39

[1]

Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019

Theo Vos, Stephen S Lim, Cristiana Abbafati et al.

The Lancet 10.1016/s0140-6736(20)30925-9

[2]

2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: Executive Summary

Jennifer S. Lawton, Jacqueline E. Tamis-Holland, Sripal Bangalore et al.

Journal of the American College of Cardiology 10.1016/j.jacc.2021.09.005

[3]

Myocardial ischaemia–reperfusion injury and cardioprotection in perspective

Gerd Heusch

Nature Reviews Cardiology 10.1038/s41569-020-0403-y

[4]

Heusch G. Eur. Heart J. (2017)

[5]

Zhang Y. Oxid. Med. Cell Longev (2021)

[6]

10.1038/nm1577

[7]

10.1016/j.freeradbiomed.2015.06.018

[8]

10.3389/fonc.2019.00696

[9]

Meng J. Am. J. Transl. Res. (2016)

[10]

10.1016/j.freeradbiomed.2022.03.010

[11]

10.1186/s12931-021-01740-w

[12]

10.1038/s41467-018-06630-2

[13]

10.1002/adhm.201900157

[14]

10.1038/ncomms9785

[15]

10.1002/adma.201301655

[16]

10.1002/anie.200200550

[17]

10.1021/cr970143c

[18]

10.1081/bio-200046659

[19]

An Osimertinib-Perfluorocarbon Nanoemulsion with Excellent Targeted Therapeutic Efficacy in Non-small Cell Lung Cancer: Achieving Intratracheal and Intravenous Administration

Jie Yang, Yingbo Li, Jiemei Sun et al.

ACS Nano 10.1021/acsnano.2c04159

[20]

10.1152/ajpcell.00152.2021

[21]

10.1038/s41569-021-00506-7

[22]

10.1126/scitranslmed.aan8840

[23]

Qian L. Oxid. Med. Cell Longev. (2019)

[24]

10.1155/2020/8384742

[25]

10.1111/jcmm.16863

[26]

10.1016/j.lfs.2021.119248

[27]

10.1002/anie.202114594

[28]

10.1021/acsami.9b20053

[29]

Therapeutic gas delivery strategies

Wanjun Gong, Chao Xia, Qianjun He

WIREs Nanomedicine and Nanobiotechnology 10.1002/wnan.1744

[30]

10.1002/advs.202101965

[31]

10.1007/s00395-022-00928-5

[32]

10.1002/adhm.201900463

[33]

10.1148/radiol.13120789

[34]

Winter P. M. Cancer Res. (2003)

[35]

10.7150/thno.21466

[36]

10.1016/j.biomaterials.2020.120621

[37]

An Osimertinib-Perfluorocarbon Nanoemulsion with Excellent Targeted Therapeutic Efficacy in Non-small Cell Lung Cancer: Achieving Intratracheal and Intravenous Administration

Jie Yang, Yingbo Li, Jiemei Sun et al.

ACS Nano 10.1021/acsnano.2c04159

[38]

10.1161/circresaha.120.318629

[39]

10.1038/s41392-021-00699-w

Metrics

15

Citations

39

References

Details

Published: Aug 18, 2023
Vol/Issue: 10(29)
License: View

Authors

C

Chaoqun Nie

Department of Cardiology The Fourth Hospital of Harbin Medical University 150000 Harbin P. R. China

R

Rong A

Department of Nuclear Medicine The Fourth Hospital of Harbin Medical University 150000 Harbin P. R. China; NHC Key Laboratory of Molecular Probe and Targeted Theranostics Molecular Imaging Research Center (MIRC) of Harbin Medical University 150000 Harbin P. R. China

J

Jing Wang

Department of Nuclear Medicine The Fourth Hospital of Harbin Medical University 150000 Harbin P. R. China; NHC Key Laboratory of Molecular Probe and Targeted Theranostics Molecular Imaging Research Center (MIRC) of Harbin Medical University 150000 Harbin P. R. China

S

Shuang Pan

Department of Cardiology The Fourth Hospital of Harbin Medical University 150000 Harbin P. R. China

R

Rentong Zou

Department of Cardiology The Fourth Hospital of Harbin Medical University 150000 Harbin P. R. China

B

Bin Wang

Department of Cardiology The Fourth Hospital of Harbin Medical University 150000 Harbin P. R. China

S

Shuiqing Xi

Department of Cardiology The Fourth Hospital of Harbin Medical University 150000 Harbin P. R. China

X

Xiaojian Hong

Department of Cardiology The Fourth Hospital of Harbin Medical University 150000 Harbin P. R. China

M

Meifang Zhou

Department of Nuclear Medicine The Fourth Hospital of Harbin Medical University 150000 Harbin P. R. China; NHC Key Laboratory of Molecular Probe and Targeted Theranostics Molecular Imaging Research Center (MIRC) of Harbin Medical University 150000 Harbin P. R. China

H

Haoyu Wang

Department of Nuclear Medicine The Fourth Hospital of Harbin Medical University 150000 Harbin P. R. China; NHC Key Laboratory of Molecular Probe and Targeted Theranostics Molecular Imaging Research Center (MIRC) of Harbin Medical University 150000 Harbin P. R. China

M

Mengshu Yu

Department of Cardiology The Fourth Hospital of Harbin Medical University 150000 Harbin P. R. China

L

Lina Wu

Department of Nuclear Medicine The Fourth Hospital of Harbin Medical University 150000 Harbin P. R. China; NHC Key Laboratory of Molecular Probe and Targeted Theranostics Molecular Imaging Research Center (MIRC) of Harbin Medical University 150000 Harbin P. R. China

X

Xilin Sun

Department of Nuclear Medicine The Fourth Hospital of Harbin Medical University 150000 Harbin P. R. China; NHC Key Laboratory of Molecular Probe and Targeted Theranostics Molecular Imaging Research Center (MIRC) of Harbin Medical University 150000 Harbin P. R. China

W

Wei Yang

Department of Cardiology The Fourth Hospital of Harbin Medical University 150000 Harbin P. R. China

Funding

National Natural Science Foundation of China Award: 81871459

Cite This Article

Chaoqun Nie, Rong A, Jing Wang, et al. (2023). Controlled Release of Hydrogen‐Carrying Perfluorocarbons for Ischemia Myocardium‐Targeting 19F MRI‐Guided Reperfusion Injury Therapy. Advanced Science, 10(29). https://doi.org/10.1002/advs.202304178

Controlled Release of Hydrogen‐Carrying Perfluorocarbons for Ischemia Myocardium‐Targeting 19F MRI‐Guided Reperfusion Injury Therapy

You May Also Like